Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability By: CannabisNewsWire July 29, 2021 at 13:49 PM EDT Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses The company envisions building on its recent successes with larger studies of the DehydraTECH process in animals infected with viruses such as SARS-CoV-2/COVID-19 or HIV/AIDS and hopes to eventually form partnerships with established pharmaceutical giants Oral drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX)provided investors an update July 22 on the success of its efforts to advance its proprietary technology toward scalable commercial use for improving the treatment of select viral illnesses. Lexaria has met three primary objectives in its investigation of antiviral drug conversion process outcomes as the antiviral drugs are processed with Lexaria’s patented DehydraTECH, according to the company’s… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office Editor@CannabisNewsWire.com CannabisNewsWire is part of the InvestorBrandNetwork. Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability By: CannabisNewsWire July 29, 2021 at 13:49 PM EDT Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses The company envisions building on its recent successes with larger studies of the DehydraTECH process in animals infected with viruses such as SARS-CoV-2/COVID-19 or HIV/AIDS and hopes to eventually form partnerships with established pharmaceutical giants Oral drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX)provided investors an update July 22 on the success of its efforts to advance its proprietary technology toward scalable commercial use for improving the treatment of select viral illnesses. Lexaria has met three primary objectives in its investigation of antiviral drug conversion process outcomes as the antiviral drugs are processed with Lexaria’s patented DehydraTECH, according to the company’s… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office Editor@CannabisNewsWire.com CannabisNewsWire is part of the InvestorBrandNetwork.
Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses The company envisions building on its recent successes with larger studies of the DehydraTECH process in animals infected with viruses such as SARS-CoV-2/COVID-19 or HIV/AIDS and hopes to eventually form partnerships with established pharmaceutical giants Oral drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX)provided investors an update July 22 on the success of its efforts to advance its proprietary technology toward scalable commercial use for improving the treatment of select viral illnesses. Lexaria has met three primary objectives in its investigation of antiviral drug conversion process outcomes as the antiviral drugs are processed with Lexaria’s patented DehydraTECH, according to the company’s… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office Editor@CannabisNewsWire.com CannabisNewsWire is part of the InvestorBrandNetwork.